https://markets.businessinsider.com/news/stocks/okyo-announces-fda-authorized-single-patient-expanded-ind-for-urcosimod-1035741971
Okyo announces FDA authorized single-patient expanded IND for urcosimod | Markets Insider
OKYO Pharma (OKYO) announced that the U.S. Food and Drug Administration, FDA, has authorized a single-patient expanded access Investigational Ne...
https://www.globenewswire.com/news-release/2025/05/01/3072233/0/en/FDA-Grants-OKYO-Pharma-Fast-Track-Designation-to-Urcosimod-for-Neuropathic-Corneal-Pain.html
FDA Grants OKYO Pharma Fast Track Designation to Urcosimod
LONDON and NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is...
fast track designationfdagrantsokyopharma
https://markets.businessinsider.com/news/stocks/okyo-pharma-announces-highlights-from-type-c-meeting-with-fda-on-urcosimod-1035756804
Okyo Pharma announces highlights from Type C meeting with FDA on urcosimod | Markets Insider